Aurinia Pharmaceuticals Inc
Follow $AUPH
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AUPH by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AUPH moving today?
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AUPH overview
Related filings and maps
Congress activity in AUPH
No receipt-qualified Congressional disclosure is present for AUPH in the cached public ledger.
AUPH contract awards, year to date.
Public federal awards linked to this ticker.
AUPH lobbying filings, year to date.
Registered lobbying filings matched to Aurinia Pharmaceuticals Inc.